Show simple item record

dc.contributor.advisorGrallert, Dr.Beata
dc.contributor.advisorUrbanucci, Dr. Alfonso
dc.contributor.advisorEngedal, Dr. Nikolai
dc.contributor.authorShanima Shanu, Mirza
dc.date.accessioned2022-01-07T12:53:44Z
dc.date.available2022-01-07T12:53:44Z
dc.date.issued2021
dc.identifier.urihttps://hdl.handle.net/11250/2836512
dc.description.abstractProstate cancer (PC) is the second most common cancer in men worldwide. Primary PC is treated by surgery, radiotherapy or high dose-rate brachytherapy and androgen deprivation therapy (ADT) – and this is usually very effective initially. However, most of the PC patients relapse after ADT and progress to castration-resistant prostate cancer (CRPC), which is not curable. General control nonderepressible 2 (GCN2) is a protein kinase, best known for its important role in the response to nutritional changes such as shortage of amino acids and glucose, as well as in other stresses. Since cancer cells are often in a hostile microenvironment, the standing view is that GCN2 is important for cancer cells to survive and thrive. However, the importance of GCN2 in the context of PC has not been studied. This project aimed to explore the role and regulation of GCN2 in PC, as well as that of a known activator, GCN1, to address whether GCN2 might be an effective therapeutic target for the treatment of prostate cancer.en_US
dc.language.isoengen_US
dc.publisherOsloMet-Storbyuniversiteteten_US
dc.subjectAndrogenen_US
dc.subjectCombinbation therapyen_US
dc.subjectProstate canceren_US
dc.subjectGCN2en_US
dc.subjectGCN1en_US
dc.titleGeneral control nonderepressible two (GCN2) as a therapeutic target for prostate canceren_US
dc.typeMaster thesisen_US
dc.description.versionpublishedVersionen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record